Hepatitis C Treatment Trends Examined in Comprehensive FirstWord Research Report Available at MarketPublishers.com
31 Jan 2014 • by Natalie Aster
LONDON – The approval of Sovaldi, Gilead’s once-daily oral nucleotide analogue polymerase inhibitor, at the end of 2013 ushers in a new stage in the treatment of hepatitis C virus (HCV) infection. With efficacy more than 90% in patients with HCV genotypes 1, 2, 3 or 4 infection, this safe, best-in-class therapy symbolises a true paradigm shift in comparison with the protease inhibitors (PIs) and interferon regimens. With convenient, less risky, and efficient therapies coming through the HCV drug pipeline, the battle among major competitors to transform the potentially profitable marketplace will likely be fierce.
The HCV market is on the road of turning into one of the most rapidly expanding markets in the pharmaceutical industry during the next ten years due to huge unmet needs, a sizable patient pool (170 million), and fast-moving advances in the clinic. The management of the disease is on the verge of explosion that will introduce remarkable changes to the treatment pattern.
Comprehensive research report “Hepatitis C: Game changing regimens to revolutionise treatment landscape - KOL Insight” elaborated by FirstWord highlights the most prominent insights obtained from the world’s twelve leading key opinion leaders on how HCV clinical research is expected to shape the market in the upcoming years.
The report pinpoints and examines the trends currently driving and shaping the world HCV HCV treatment landscape; gives an assessment of the potential (both commercial and clinical) of the pipeline nucs, non-nucs, NS5A inhibitors and next-gen protease inhibitors; discovers the unmet needs and identifies key opportunities for the infectious disease management; evaluates the activities of companies with the strongest pipelines of new products; as well as scrutinises the key factors expected to drive the trends in HCV infection treatment in the offing. KOL’s views on the usefulness of existing classes of HCV drugs, current research, the price of newer drugs, among other concerns, are given as well.
Hepatitis C: Game changing regimens to revolutionise treatment landscape - KOL Insight
Published: December, 2013
Price: US$ 4,995.00
Other Reports by FirstWord Include:
- Designing Clinical Trials to Show Value
- Physician Views: Sanofi's successor to Lantus - are endocrinologists impressed?
- Physician Views: Bayer's M&A catalyst – is Xofigo a paradigm shifter for the prostate cancer market?
More in-demand reports by the publisher can be found at FirstWord page.